

DAFTAR PUSTAKA

1. Angus DC, Poll T. Severe sepsis and septic shock. *N Engl J Med.* 2013; 369: 840-51.
2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, *et al.* Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Society of critical care medicine and the European society of intensive care medicine. 2013; 41 (2): 580-637.
3. Abad CL, Kumar A, Safdar N. Antimicrobial therapy of sepsis and septic shock—when are two drugs better than one?. *Crit Care Clin.* 2011; 27: e1–e27.
4. Rosa RD, Pietrosanti M, Luzi G, Salemi S, D'Amelio R. Review article, Polyclonal intravenous immunoglobulin: An important additional strategy in sepsis?. *European Journal of Internal Medicine.* 2014; 25: 511–16.
5. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, *et al.* Sepsis in European intensive care units: results of the SOAP study. *Crit. Care Med.* 2006; 34(2): 344-53.
6. Ricardo C, Juan Z, Eberhard S, George H. Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department, *Clinica Chimica Acta.* 2015: 1-30.
7. Chen CC, Chong CF, Liu YL, Chen KC, Wang TL. Risk stratification of severe sepsis patients in the emergency department. *Emerg. Med. J.* 2006; 23: 281-5.
8. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, *et al.* Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest.* 1992; 101: 1644-55.
9. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, *et al.* 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med.* 2003; 31: 1250–56.
10. Chen XH, Yin YJ, Zhang JX. Sepsis and immune response. *World J Emerg Med.* 2011; 2(2): 88-92.
11. Pardede DKB, Siahaan D. Eosinopenia sebagai penanda diagnosis sepsis. *CDK-221.* 2014; 41(10): 741-44.

12. Nguyen HB, Rivers EP, Abrahamian FM, Moran GJ, Abraham E, Trzeciak S, *et al.* Severe sepsis and septic shock: Review of the literature and emergency department management guidelines. *Ann Emerg Med.* 2006;48:28-54.
13. Vodnik T, Kaljevic G, Tadic T, Singh NM. Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis. *Clin Chem Lab Med.* 2013: 1-10.
14. Novelli G, Morabito V, Ferretti G, Pugliese F, Ruberto F, Venuta F, *et al.* Pathfast Presepsin assay for early diagnosis of bacterial infections in surgical patients: Preliminary study. *Transplantation proceedings, Elsevier.* 2013; 45: 2750-3.
15. Agilli M, Sener I, Yesildal F, Honca T, Aydi I, Akgul EO, *et al.* A new marker for the diagnosis of sepsis: Presepsin. *J Investig Biochem.* 2012; 1(1): 55-7.
16. Mussap M, Puxeddu E, Burrai P, Noto A, Cibecchini F, Testa M, *et al.* Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges. *J Matern Fetal Neonatal Med.* 2012; 25(5): 51-3.
17. Endo S, Takahashi T, Shozushima T, Matsumoto N, Kojika M, Suzuki Y, *et al.* Usefulness of Presepsin (Soluble CD14 Subtype) as a diagnostic marker for sepsis. *JJAAM.* 2012; 23: 27-38.
18. Stojkovic MV, Vuk Lj, Jovic M, Filipovic M, Milinovic BT, Stojkovic B, *et al.* Levels of Presepsin and Midregion-Proadrenomedullin in septic patients with end-stage renal disease after cardiovascular surgery: 1-year follow up study. *J Clin Exp Cardiol.* 2014; 5: 5.
19. Kota SK, Meher LK, Rao ES, Jammula S, Kota SK, Modi KD. Review article. Utility of biomarkers in sepsis: mirror reflection of inner truculent devil. *Bangladesh Journal of Medical Science.* 2013; 12: 17-29.
20. Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, *et al.* Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. *Critical Care.* 2013; 17: R168.
21. Liu B, Chen YX, Yin Q, Zhao YZ, Li CS. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. *Critical Care.* 2013; 17: R244.
22. Zou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. *World J Emerg Med.* 2014; 5(1): 16-9.

23. Ramana KV, Pinnelli VBK, Kandi S, Asha G, Jayashankar CA, Bhanuprakash, *et al.* Presepsin: A novel and potential diagnostic biomarker for sepsis. *American Journal of Medical and Biological Research*. 2014; 2(4): 97-100.
24. Camacho CH, Losa J. Biomarkers for sepsis. *BioMed Research International*. 2014: 1-6.
25. Beňovska M, Bučkova D, Petříkova D, Stašek J, Gottwaldova J. Presepsin as a diagnostic and prognostic tool for sepsis. *Klin. Biochem. Metab.*, 23 (44), 2015, No. 3, p. 89–94.
26. Behnes M, Bertsch T, Lepiorz D, Lang S, Trinkmann F, Martina B, *et al.* Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. *Critical Care*. 2014, 18: 507.
27. Vincent JL, Moreno R. Clinical review: Scoring systems in the critically ill. *Critical Care*. 2010; 14: 207.
28. Arabi Y, Al Shirawi N, Memish Z, Venkatesh S, Al-Shimemeri A. Assessment of six mortality prediction models in patients admitted with severe sepsis and septic shock to the intensive care unit: a prospective cohort study. *Critical Care*. 2003; 7: R116-R122.
29. Shapiro NI, Howell MD, Talmor D, Donnino M, Ngo L, Bates DW. Mortality in Emergency Department Sepsis (MEDS) score predicts 1-year mortality. *Crit Care Med*. 2007; 35: 192–8.
30. Putra BE, Tiah L. *Review Article*, The Mortality in emergency department sepsis score as a predictor of 1-month mortality among adult patients with sepsis: Weighing the Evidence. *ISRN Emergency Medicine*. 2013: 1-6.
31. Artero A, Zaragoza R, Nogueira JM. Epidemiology of severe sepsis and septic shock. Understanding a serious killer. 2012: 1-23. Available from <http://www.intechopen.com>.
32. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med*. 2003; 348: 1546-54.
33. Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE. Long-term mortality and quality of life in sepsis: A systematic review. *Crit Care Med*. 2010; 38: 1276–83.
34. Booker E. Sepsis, severe sepsis, and septic shock: current evidence for emergency department management. *Ebmedicine.net*. 2011; 13(5): 1-24.

35. Morrell MR, Micek ST, Kollef MH. The management of severe sepsis and septic shock. *Infect Dis Clin N Am*. 23.2009:485-501.
36. Yohannes, Evy. Pola penggunaan antimikroba pada penderita sepsis rawat inap di RSK ST. Vincentius A Paulo Surabaya Pada Tahun 1998 – 2001. 2002.
37. Sjahrurachman A, Ikaningsih. Profil etiologi bakteremi dan resistensinya terhadap antibiotik di rumah sakit Cipto Mangunkusumo, Jakarta tahun 1999-2002. *MKI*, vol: 54, no: 7. Juli 2004; 260-5.
38. Oktaviani. Efektivitas terapi antibiotik pada pengobatan sepsis untuk pasien dewasa yang menjalani rawat inap di RSUP Dr. Sardjito Yogyakarta Selama Tahun 2007. Universitas Islam Indonesia. 2008.
39. Setiawan MW, Pujo JL, Lestari ES. Pola kuman pasien yang dirawat di ruang rawat intensif RSUP Dr. Kariadi Semarang. Fakultas Kedokteran Universitas Diponegoro Semarang. 2010 : 1-18.
40. Sodik DC. Pola penggunaan antibiotik dan pola kuman pada pasien sepsis rawat inap RSUP Dr. Hasan Sadikin Bandung. Fakultas Farmasi Universitas Padjadjaran Jatinangor. 2012.
41. Cohen J. The immunopathogenesis of sepsis. *NATURE*. 2002; 420: 885-91.
42. Sumantri S. Tinjauan imunopatogenesis dan tatalaksana sepsis. Departemen Ilmu Penyakit Dalam FKUI/RSUPNKM Jakarta. 2012: 1-36.
43. *Imunologi Infeksi. Imunologi Dasar edisi ke-8*. 399-449.
44. Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis : New clinical and analytical perspectives for two old biomarkers. *The Journal of Maternal Fetal and Neonatal Medicine*. 2011; 24(2): 12-4.
45. Le Roy D, Di Padova F, Adachi Y, Glauser MP, Calandra T, Heumann D. Critical role of lipopolysaccharide-binding protein and cd14 in immune responses against gram-negative bacteria. *J Immunol*. 2001; 167: 2759-65.
46. Pazidis A, Champipis A, Gkoukourelias I, Boura P. CD14/TLR4 in sepsis pathogenesis and therapy. *Aristotle University Medical Journal*. 2012; 39(1): 19-28.
47. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. *Clinical Microbiology Reviews*. 2009; 2(2): 240–73.
48. Liu SF, Malik AB. NF-kB activation as a pathological mechanism of septic shock and inflammation. *Am J Physiol Lung Cell Mol Physiol*. 2006; 290: L622–L645.

49. Russell JA. Management of sepsis. *N Engl J Med* 2006;355:1699-713.
50. Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. *J Infect Chemother* 2005;11:234-238.
51. Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. *Critical Care*. 2014; 18: R6.
52. Pizzolato E, Ulla M, Galluzzo C, Lucchiari M, Manetta T, Lupia E, et al. Role of presepsin for the evaluation of sepsis in the emergency department. *Clin Chem Lab Med*. 2014; 52(10):1395-400.
53. Nakamura Y, Ishikura H, Nishida T, Kawano Y, Yuge R, Ichiki R, et al. Usefulness of presepsin in the diagnosis of sepsis in patients with or without acute kidney injury. *BMC Anesthesiology*. 2014; 14: 88.
54. Spanuth E, Ebelt H, Ivandic B, Werdan K. Diagnostic and prognostic value of presepsin (soluble CD14 subtype) in emergency patients with early sepsis using the new assay PATHFAST Presepsin. 21st International Congress of Clinical Chemistry and Laboratory Medicine, IFCC-WorldLab – EuroMedLab, Berlin. 2011: 1-4.
55. Nakamura M, Takeuchi T, Naito K, Shirakawa K, Hosaka Y, Yamasaki F, et al. Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model. *Critical Care*. 2008; 12(2): P194
56. Shirakawa K, Naitou K, Hirose J, Nakamura M, Takeuchi T, Hosaka Y, et al. The new sepsis marker, sCD14-ST, induction mechanism in the rabbit models. Mochida Pharmaceutical Co., Ltd, Pharmaceutical Research Center, Gotemba, Japan. *Critical Care*. 2010; 14(2): P19.
57. Shozushima T, Takahashi T, Matsumoto N, Kojika M, Okamura Y, Endo S, et al. Usefulness of Presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. *J Infect Chemother*. 2011: 1-6.
58. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. *J Infect Chemother*. 2012: 1-7.

59. Fukui Y, Okamura Y. Clinical performance of a point-of-care assay for measurement of presepsin in patients with bacteremia. *Crit Care*. 2013; 13(4): P58
60. Sato M, Takahashi G, Shibata S, Onodera M, Suzuki Y, Inoue Y, et al. Clinical performance of a new soluble CD14-subtype immunochromatographic test for whole blood compared with chemiluminescent enzyme immunoassay: use of quantitative soluble CD14-subtype immunochromatographic tests for the diagnosis of sepsis. *PLOS ONE* 10(12): 2015; e0143971.
61. Gobeaux CC, Trabattoni E, Roelens M, Borderie D, Claessens YE. Presepsin (sCD14-ST) in emergency department: The need for adapted threshold values?. *Clinica Chimica Acta*. 2014; 427: 34–6.
62. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: A multicenter prospective study. *J Infect Chemother*. 2014; 20: 30-4.
63. Zoubi NOG, Vardi M, Laor A, Weber G, Bitterman H. Assessment of disease-severity scoring systems for patients with sepsis in general internal medicine departments. *Critical Care*. 2011; 15: R95.
64. Hermans MAW, Leffers P, Jansen LM, Keulemans YC, Stassen PM. The value of the Mortality in Emergency Department Sepsis (MEDS) score, C reactive protein and lactate in predicting 28-day mortality of sepsis in a Dutch emergency department. *Emerg Med J*. 2012; 29: 295-300.
65. Irawan D, Hamidah, Purwati, Triyono EA, Bramantono, Arfianto V, et al. Profil penderita sepsis akibat bakteri penghasil ESBL. Departemen Ilmu Penyakit Dalam FK Unair/RSUD Dr Soetomo Surabaya. *J Peny Dalam*. 2012; 13(1).
66. Hall MJ, Williams SN, DeFrances CJ, Golosinskiy A. Inpatient care for septicemia or sepsis: A challenge for patients and hospitals. *inpatient care for septicemia or sepsis: A challenge for patients and hospitals*. NCHS data brief, no 62. Hyattsville, MD: National Center for Health Statistics. 2011.
67. Wiraatmaja I, Oktaliansah E, Maskoen TT. CO₂ Gap sebagai prediktor tingkat mortalitas pasien sepsis berat di *Intensive Care Unit*. *Jurnal Anestesi Perioperatif*. JAP. 2014;2(3): 194–9.
68. Suryanto Ca. Uji diagnostik prokalsitonin dibanding kultur darah sebagai baku emas untuk diagnosis sepsis bakterial di RSUP Dr.Kariadi. 2012: 1-62.

69. Abe R, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Tateishi Y, *et al.* Gram-negative bacteremia induces greater magnitude of inflammatory response than Gram-positive bacteremia. Abe et al. *Critical Care* 2010, 14:R27.
70. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, *et al.* International study of the prevalence and outcomes of infection in Intensive Care Units. *JAMA*. 2009;302(21):2323-2329.
71. Sandiana A.T. Pola penggunaan antibiotik dan pola kuman pada pasien sepsis di salah satu rumah sakit swasta di kota Bandung. Universitas Padjajaran. 2012.
72. Mahendra A.D. Pola kuman dan resistensinya pada pasien sepsis dewasa terhadap antibiotik di RSUD Dr. Moewardi Tahun 2014. Universitas Muhammadiyah Surakarta Surakarta 2015; 1-15.
73. Guntur A. Sepsis dalam : Prasetyo DH, Sutanto SY, editor. SIRS dan sepsis (immunologi, diagnosis, penatalaksanaan). Surakarta : Sebelas Maret University Press; 2006.p.1-14.
74. Hamishehkar H, Beigmohammadi MT, Abdollahi M, Ahmadi A, Mahmoodpour A, Mirjalil MR, *et al.* Identification of enhanced cytokine generation following sepsis. Dream of magic bullet for mortality prediction and therapeutic evaluation. *DARU* 2010; 18 (3): 155-62.
75. Dreyer AW. Blood Culture Systems: From patient to result. In : Sepsis – An ongoing and significant challenge. *InTech*; 2012. p. 287-310.
76. Shelly TN. Profil dan pola resistensi bakteri dari kultur darah terhadap sefalosporin generasi ketiga di laboratorium mikrobiologi klinik FK UI Tahun 2001-2006. 2009; 4-14.
77. Pneumonia nosokomial pedoman diagnosis & penatalaksanaan di indonesia. Perhimpunan Dokter Paru Indonesia. 2003; 1-17.
78. Aryati MS. Perbandingan presepsin dan procalcitonin sebagai penanda penderita sepsis. Universitas Airlangga. 2012: 1-12.
79. Spanuth E, Ebelt H, Ivandic B, Werdan K. The new sepsis marker presepsin is superior for prognosis and disease monitoring compared to procalcitonin. 20th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine. 2013.
80. Crowe CA, Kulstad EB, Mistry CD, Kulstad CE. Comparison of severity of illness scoring systems in the prediction of hospital mortality in severe sepsis and septic shock. *J Emerg Trauma Shock*. 2010 Oct-Dec; 3(4): 342–347.

81. Spanuth E, Ivandic B, Wilhelm J, Thomac R, Werdan K. Combination of the Mortality in Emergency Department Sepsis (MEDS) Score with PATHFAST presepsin improves outcome prediction of sepsis. *Diagnostics Engineering & Research. (Abstract)*; 2015.
82. Carpenter C.R, Pines J.M, Raja A.S, Schuur J.D. Evidence-based emergency care: Diagnostic testing and clinical decision rules. *Sepsis, Chapter 33. Wiley; (33) 2012.*
83. Chen HC, Lin WL, Lin CC, Hsieh WH, Hsieh CH, Wu MH, *et al.* Outcome of inadequate empirical antibiotic therapy in emergency department patients with community-onset bloodstream infections. *J Antimicrob Chemother. 2012;1-7.*

